Degroof Petercam - Warehouses De Pauw SCA (WDP) WDP - A defensive logistics profile

Report

Degroof Petercam

Inna Maslova

WDP - A defensive logistics profile

A defensive logistics profile

03/07/2023 1 EN

Underlying

Warehouses De Pauw SCA

Warehouses De Pauw and its subsidiaries are engaged in investment in the Belgian semi-industrial property market. Co. is a closed-end property investment company which specializes in: development of storage and distribution premises; customized projects in line with the user's request; acquiring premises for customers who wish to engage in sale and leaseback transactions.

See profile

BE0003763779 Belgium

Provider

Degroof Petercam

We are an investment house with Belgian roots founded on more than 150 years of trust.

As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.

See profile

Analysts

Inna Maslova

Other Reports on these Companies

SmartInsider

Warehouses De Pauw SA: 3 directors

Three Directors at Warehouses De Pauw SA bought 27,750 shares at between 20.480EUR and 20.612EUR. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under li...

Free Trial

November 21, 2024 November 21, 2024 1 EN

Degroof Petercam

WDP - In-line Q1, portfolio seeing signs of stabilisation

Q1 property result stood at EUR 89.5m, up 9.6% YoY. LfL rental growth stood at 3.5%, driven primarily by lease indexation with -0.5% impact from increased vacancy. The reversionary potential on the existing portfolio stands at ca. 13%.Operating margin declined 290bps since December end to 88.6% as a result of G&A expenses increasing ca. 75% YoY and property charges being up 23.7% (rental income up 11.8%).Portfolio EPRA NIY remained flat at 5.3%, with portfolio witnessing a +EUR 26m revaluation (+0.4% QoQ) ‘Hold' rating reiterated on the back of demanding multiples.WDP reiterates its 2024 ...

April 19, 2024 April 19, 2024 1 EN

ING Financial Markets

Benelux Morning Notes

Belgian telecoms: Wyre reached 44k homes passed at end 2023, below 100k ambition. Corbion: A long time coming. DWS: Promises, promises. PostNL: Preliminary 4Q23 - profit warning on weaker parcel volumes and fixed capacity. Signify: 4Q23 Results - weak top line, margins protected. WDP: 2024-27 ambitions revealed

January 26, 2024 January 26, 2024 1 EN

(Sponsored) Whitestone Group - H1-24: Very active first half and ready to invest

Whitestone's NAV almost tripled in size over H1 from EUR 34.4m to EUR 99.7m at June 30.The majority of the immense growth is thanks to two capital raises with in total EUR 59.7m raised.The remainder of the growth comes from the solid performance in the portfolio (+EUR 6m).The company still has more than EUR 20m in cash available to deploy, even after its most recent investment in Lambda X Ophtalmics.We estimate today's NAV at EUR 14.5 p/s implying a discount of 16.5%. Our TP moves to EUR 13.4 (was EUR 13.9) and we reiterate our Hold rating.

October 28, 2024 October 28, 2024 1 EN

David Seynnaeve ... (+2)

David Seynnaeve
PhD

(Sponsored) Oncodesign Precision Medicine - Final Ph1 results of RIPK2 inhibitor OPM-101 paving the way for Ph1b/2a launch

*OPM reported the final results of its Ph1 study with RIPK2 inhibitor ‘OPM-101'. Ph1b/2a expected to launch early 2025.*While results look highly encouraging, with strong safety data and no cardiac toxicity, we await clarity on the Ph1b/2a trial protocol and pursued indication.*Our rNPV-based valuation takes into account estimates related to OPM-101 and OPM-201 and does not factor in the potential dilutive impact of any future capital raises. Discovery/preclinical-stage programs are considered upside for the time being. We recommend to Buy the stock considering the attractive 66% upside a...

October 23, 2024 October 23, 2024 1 EN

Luuk Van Beek

Luuk Van Beek

(Sponsored) Cabka - Encouraging sales trend in Q3

Q3-24 sales increased 8% to EUR 42.4m, showing an encouraging sequential trendManagement reiterates its guidance for EUR 180-185m in revenues and a 13-15% EBITDA margin in 2024We will fine-tune our estimates and reiterate our Buy and EUR 4.60 TP

October 21, 2024 October 21, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

WDP - A defensive logistics profile

Warehouses De Pauw SA: 3 directors

WDP - In-line Q1, portfolio seeing signs of stabilisation

Benelux Morning Notes

(Sponsored) Whitestone Group - H1-24: Very active first half and ready to invest

(Sponsored) Oncodesign Precision Medicine - Final Ph1 results of RIPK2 inhibitor OPM-101 paving the way for Ph1b/2a launch

(Sponsored) Cabka - Encouraging sales trend in Q3

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe